stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
29.94
0.20
−0.66%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Debt to equity
Vera Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.2×, up 0.1× from fiscal 2025 (0.1×). Over the past ten years it has ranged from 0.0× (fiscal 2020) to 0.5× (fiscal 2023); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.1× | 41.00% |
| FY2024 | 0.1× | (82.10%) |
| FY2023 | 0.5× | 52.05% |
| FY2022 | 0.3× | 356.29% |
| FY2021 | 0.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.2× | 22.92% |
| Mar 2026 | 0.2× | 21.24% |
| Dec 2025 | 0.1× | (33.83%) |
| Sep 2025 | 0.2× | 17.67% |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.5×
Ten-year median
0.1×
Current reading's percentile
71
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BHVN Biohaven Ltd. compare | −2.7× |
| PVLA Palvella Therapeutics, Inc. compare | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| VCEL Vericel Corporation compare | 0.0× |
| IMNM Immunome, Inc. compare | 0.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| CLDX Celldex Therapeutics, Inc. compare | 0.0× |
| AUPH Aurinia Pharmaceuticals Inc compare | 0.1× |
| VERA Vera Therapeutics, Inc. | 0.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)